Vertex cystic fibrosis drug gets expanded approval for use in infants [Reuters (UK)]
Vertex Pharmaceuticals Incorporated (VRTX)
Last vertex pharmaceuticals incorporated earnings: 4/29 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.vrtx.com
Company Research
Source: Reuters
Vertex cystic fibrosis drug gets expanded approval for use in infants | Reuters Reuters Staff 2 Min Read (Reuters) - U.S. health regulators have expanded the use of one of Vertex Pharmaceuticals Inc’s cystic fibrosis drugs to include patients aged between 12 months and 24 months. The expanded approval makes Kalydeco the first medicine to treat the underlying cause of the genetic disease in this age group among patients with specific mutations in the CF transmembrane regulator (CFTR) gene, Vertex said on Wednesday. The drug is currently approved in the United States to treat patients aged 2 and older whose CFTR gene has certain mutations. There are few treatment options for the 70,000 cystic fibrosis patients worldwide who rarely live beyond 40 and possess a defective gene that leads to the build-up of thick mucus which clogs the lungs and other organs. The approval is based on data from an ongoing late-stage safety study in 25 children who have one of 10 mutations in the CFTR gene, th
Show less
Read more
Impact Snapshot
Event Time:
VRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
VRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
VRTX alerts
High impacting Vertex Pharmaceuticals Incorporated news events
Weekly update
A roundup of the hottest topics
VRTX
News
- Cystic Fibrosis Market Pipeline Insights Report 2024 Featuring 75+ Companies and 80+ Pipeline Drugs, Including VX-121 (Vertex Pharma), Brensocatib (AstraZeneca), ELX-02 (Eloxx Pharma), and S-1226 (SolAeroMed) [Yahoo! Finance]Yahoo! Finance
- Vertex Pharma scientist talks about the long road to developing non-addictive painkillers [Financial Post (Toronto, Ontario, Canada)]Financial Post
- Vertex Pharma scientist talks about the long road to developing non-addictive painkillers [Yahoo! Finance]Yahoo! Finance
- Investors Heavily Search Vertex Pharmaceuticals Incorporated (VRTX): Here is What You Need to Know [Yahoo! Finance]Yahoo! Finance
- Here's (at Least) 1 new Reason to Buy Vertex Pharmaceuticals Stock [Yahoo! Finance]Yahoo! Finance
VRTX
Earnings
- 2/5/24 - Beat
VRTX
Sec Filings
- 4/11/24 - Form SC
- 4/11/24 - Form 8-K
- 4/10/24 - Form SC
- VRTX's page on the SEC website